Clinical trials
Thyroid Associated Ophthalmopathy clinical trials
Below are recruiting thyroid associated ophthalmopathy clinical trials, each written for real people, not researchers. We’re tracking 16 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07716397Recruiting
MRI study for thyroid eye disease diagnosis and care
This study uses MRI scans of the eye area to better understand and classify thyroid eye disease (TED). It aims to help doctors predict outcomes and personalize treatment. You may be eligible if you have stable TED or are a healthy volunteer.
Shanghai, Huangpu DistrictAges 18–75 - NCT04936854RecruitingPhase 2
Sirolimus or steroid drops for active Graves eye disease
This Phase 2 study compares sirolimus versus corticosteroids to treat active thyroid eye disease. It aims to see which treatment works better to calm eye inflammation and improve symptoms, without needing urgent eye surgery.
Bergen, HordalandAges 18–80 - NCT06112340RecruitingPhase 2/Phase 3
Extension study of linsitinib for thyroid eye disease
This trial tests two doses of an oral medication (linsitinib) for people with active, moderate-to-severe thyroid eye disease who were in a previous study and didn't improve enough or had their bulging come back. It aims to see if continuing treatment can help with eye bulging and other symptoms.
Miami, FloridaAges 18 years+ - NCT06590220Recruiting
Predicting treatment needs for moderate to severe thyroid eye disease
This study aims to build a model that helps doctors predict how thyroid eye disease (TAO) will progress, specifically for patients with moderate to severe symptoms. If you have had TAO and meet the activity criteria, your participation could lead to better personalized care.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06927375RecruitingPhase 4
Combination drug therapy for thyroid eye disease
This study tests a combination of two drugs, tocilizumab and flupentixol-melitracen, in people with active, moderate-to-severe thyroid-associated eye disease (TED). It aims to see if this combination can reduce eye bulging, double vision, and anxiety symptoms.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06989918RecruitingPhase 3
Study of MHB018A for active thyroid eye disease
This trial tests a new medicine called MHB018A for people with active, moderate to severe thyroid eye disease. It aims to see if the drug can reduce eye symptoms like bulging and inflammation.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07124572Recruiting
Building a Better Diagnosis System for Thyroid Eye Disease
This study aims to build a better system for diagnosing and treating thyroid-associated ophthalmopathy (a thyroid eye condition). It may help improve care for people with this disease, and also involves healthy volunteers as a comparison group.
Hangzhou, ZhejiangAges 7–90 - NCT07381413Recruiting
Eye tracking study for thyroid eye disease
This study uses eye tracking to compare how people with thyroid eye disease move their eyes and pay attention to visual cues. It may help researchers understand eye movement problems better.
ShanghaiAges 18–70 - NCT03131726RecruitingPhase 3
Simvastatin for Graves eye disease in mild-to-moderate cases
This trial tests whether simvastatin (a cholesterol medicine) can improve eye symptoms from Graves’ eye disease. It is aimed at people with active mild-to-moderate disease and will also check safety with blood tests, heart/skin tolerance, and stomach health.
MalmöAges 18–70 - NCT06392906RecruitingPhase 3
Radiation for Graves' Eye Disease: 1 vs 2 Weeks
This trial tests if a shorter course of radiation (1 week) works as well as a standard longer course (2 weeks) for treating active thyroid eye disease that did not improve enough with steroid medicine. It may be an option if you still have eye symptoms after steroid treatment.
Bangkok NoiAges 18–70 - NCT05112211Recruiting
Imaging study of doxycycline in thyroid eye disease
This study looks at how doxycycline (an antibiotic) affects thyroid eye disease using special imaging pictures. It may help doctors better understand disease activity and how well treatments work.
Guangzhou, GuangdongAges 18–70 - NCT07152392RecruitingPhase 4
Testing IBI311 for inactive thyroid eye disease symptoms
This trial tests a medication called IBI311 for people with inactive thyroid eye disease that still causes bothersome symptoms like double vision or trouble closing the eyes. The goal is to see if it helps improve these problems safely.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07152366RecruitingPhase 4
Hormone and tetuzumab for active thyroid eye disease
This trial tests a new sequence of hormone therapy followed by a targeted drug (tetuzumab) for people with moderate to severe thyroid eye disease that is still active after steroid treatment didn't help enough.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07152340RecruitingPhase 4
Sequential hormone and IBI311 therapy for active TAO
This trial tests a two-step treatment for active, moderate-to-severe thyroid eye disease (TAO). You will first receive hormone therapy, followed by a drug called IBI311. The goal is to see if this sequence works better for people who have not had steroid treatment before.
Changhua, Shanghai MunicipalityAges 18–80 - NCT06275373Recruiting
Teprotumumab for thyroid eye disease study
This study tests if the drug teprotumumab can help with symptoms of thyroid eye disease, such as bulging eyes, pain, or double vision. It is for adults who are beneficiaries of the Department of Defense (DOD).
Bethesda, MarylandAges 18 years+ - NCT05678374Recruiting
Looking for immune signs linked to mental fatigue in Graves’ disease
This study looks at blood “immune” markers to understand why some people with Graves’ disease develop mental fatigue (feeling slowed down in thinking). It may help doctors better recognize and explain mental fatigue in Graves’ disease.
GothenburgAges 18–72
Hear when a new Thyroid Associated Ophthalmopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for thyroid associated ophthalmopathy?
- Yes. Clin2 currently lists 16 recruiting thyroid associated ophthalmopathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a thyroid associated ophthalmopathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a thyroid associated ophthalmopathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.